Pacira BioSciences (PCRX) Cash & Equivalents Growth (3y) (2013 - 2026)
Pacira BioSciences (PCRX) Cash & Equivalents Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | 21.81% |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 11.05% |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -4.92% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 7.80% |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 19.10% |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 12.11% |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 27.55% |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 13.03% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 32.82% |
| 10 | Pacira BioSciences | 970.37 Mn | 719.34 Mn | 148.24 Mn | 33.36% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 33.36% |
| Mar 31, 2026 | 59.53% |
| Dec 31, 2025 | 15.04% |
| Sep 30, 2025 | 10.49% |
| Jun 30, 2025 | 35.03% |
| Mar 31, 2025 | 7.74% |
| Dec 31, 2024 | -22.10% |
| Sep 30, 2024 | 22.43% |
| Jun 30, 2024 | 32.68% |
| Mar 31, 2024 | 40.26% |
| Dec 31, 2023 | 15.32% |
| Sep 30, 2023 | -7.50% |
| Jun 30, 2023 | 3.39% |
| Mar 31, 2023 | -13.33% |
| Dec 31, 2022 | 10.01% |
| Sep 30, 2022 | 8.72% |
| Jun 30, 2022 | 26.89% |
| Mar 31, 2022 | 1.78% |
| Dec 31, 2021 | 64.09% |
| Sep 30, 2021 | -16.59% |